The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Bavarian Nordic's ...

French health authorities have suspended the use of Valneva’s chikungunya vaccine Ixchiq in adults aged 65 and older after ...

The country is considered the epicenter of the disease in the Americas, with epidemics reported over the years.

The Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Vimkunya, a vaccine used to prevent disease caused by the chikungunya virus in people 12 years of age and older. The ...

Shares of French speciality vaccines developer Valneva (Nasdaq: VAL) were down 8.4% at 2.89 euros by early afternoon, after ...

Copenhagen, Denmark Saturday, May 3, 2025, 12:00 Hrs [IST] ...

Recommendations for the use of chikungunya vaccine were recently discussed at a meeting of the Advisory Committee on Immunization Practices.

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (1 May 2025) approved a vaccine (Vimkunya) used to ...

Shares in Valneva plunged after the company said France's health authorities suspended the use of its chikungunya vaccine, Ixchiq, for people aged 65 and older, raising concerns about the vaccine's ...

As safety flags hang over Valneva’s chikungunya vaccine in the U.S. and beyond, French authorities are clamping down on the shot’s use in older adults. | France’s public health agency has temporarily ...

Bavarian Nordic is targeting launch of the vaccine in the UK during the summer of 2025. The UK approval of VIMKUNYA marks the third approval of Bavarian Nordic's chikungunya vaccine, which was ...

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.